News | May 30, 2026
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Global specialty pipeline accelerates growth
We are building an AI-native operating system for pharma sales and distribution
Bengaluru startup targets 100+ enterprise clients and global expansion as it aims to transform pharmaceutical sales, marketing, tenders, and distribution using AI agents
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
